Building protein networks in synthetic systems from the bottom-up

Shim, Jiyoung; Zhou, Chuqing; Gong, Ting; Iserlis, Dasha Aleksandra; Linjawi, Hamad Abdullah; Wong, Matthew S.; Pan, Tingrui; Tan, Cheemeng

doi:10.1016/j.biotechadv.2021.107753

Cited by 11 publications

(6 citation statements)

References 101 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…So, molecular self-assembly is an efficient tool to characterize the unprecedented control in physical, chemical, and biological parameters over biomaterial properties. [76,116] For the design of resilient protein scaffolds in microfluidic devices [120] and viscoelastic biomaterials of biomimetic ECM microenvironment, [121] the molecular selfassembly-related bottom-up approach was typically based on chemistry performed in solution, which was easier to scale up to coordinate control of physicochemical or biological properties of biomaterials in hydrogel formulation, [122] since the physiochemical behaviors of hydrogel always depended on that of its building blocks. In the fields of natural proteins or peptides, ELPs are excellent elementary components for the bottom-up approach to develop functional hydrogel biomaterials down to nanometers in thickness, which has served as bioactive nanofiber scaffolds for both in vitro and in vivo applications.…”

Section: Molecular Self-assembly Of Designer Peptidementioning

confidence: 99%

Short Peptide Nanofiber Biomaterials Ameliorate Local Hemostatic Capacity of Surgical Materials and Intraoperative Hemostatic Applications in Clinics

et al. 2023

View full text Add to dashboard Cite

Short designer self‐assembling peptide (dSAP) biomaterials are a new addition to the hemostat group. It may provide a diverse and robust toolbox for surgeons to integrate wound microenvironment with much safer and stronger hemostatic capacity than conventional materials and hemostatic agents. Especially in noncompressible torso hemorrhage (NCTH), diffuse mucosal surface bleeding, and internal medical bleeding (IMB), with respect to the optimal hemostatic formulation, dSAP biomaterials are the ingenious nanofiber alternatives to make bioactive neural scaffold, nasal packing, large mucosal surface coverage in gastrointestinal surgery (esophagus, gastric lesion, duodenum, and lower digestive tract), epicardiac cell‐delivery carrier, transparent matrix barrier, and so on. Herein, in multiple surgical specialties, dSAP‐biomaterial‐based nano‐hemostats achieve safe, effective, and immediate hemostasis, facile wound healing, and potentially reduce the risks in delayed bleeding, rebleeding, post‐operative bleeding, or related complications. The biosafety in vivo, bleeding indications, tissue‐sealing quality, surgical feasibility, and local usability are addressed comprehensively and sequentially and pursued to develop useful surgical techniques with better hemostatic performance. Here, the state of the art and all‐round advancements of nano‐hemostatic approaches in surgery are provided. Relevant critical insights will inspire exciting investigations on peptide nanotechnology, next‐generation biomaterials, and better promising prospects in clinics.

show abstract

Section: Molecular Self-assembly Of Designer Peptidementioning

confidence: 99%

Short Peptide Nanofiber Biomaterials Ameliorate Local Hemostatic Capacity of Surgical Materials and Intraoperative Hemostatic Applications in Clinics

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Controlling the self-assembly of proteins allows the rational design and biofabrication of protein-only materials out of recombinant proteins, at the nano, micro, and macro scales. − In this sense, since proteins are fundamental macromolecules in living organisms, the biocompatibility of such materials is ensured, allowing applications in distinct biotechnological and biomedical settings, such as catalysis, drug delivery, and regenerative medicine, , for different functional, scaffolding, or drug-packaging purposes. − On the other hand, tailoring the conformation and the biological activities of protein building blocks is reachable by conventional genetic engineering, thus allowing the generation of functional materials with refined and case-adapted functionalities. Several approaches promote regular contacts between monomers for the controlled generation of supramolecular structures.…”

Section: Introductionmentioning

confidence: 99%

Biofabrication of Self-Assembling Covalent Protein Nanoparticles through Histidine-Templated Cysteine Coupling

López‐Laguna

Rueda

Martínez-Torró

et al. 2023

ACS Sustainable Chem. Eng.

View full text Add to dashboard Cite

Nanoscale protein materials show increasing applications in biotechnology and biomedicine, addressing catalysis, drug delivery, or tissue engineering. Although protein oligomerization is reachable through several engineering approaches, including the use of divalent cations for histidine-rich stretches, the effectiveness of cation-His binding is influenced by protein conformation, media composition, and chelating agents. Thus, looking for powerful, green, cross-linker-free, and transversal oligomerization platforms, we have built a histidine-templated cysteine-coupling concept. On this basis, we have engineered a Cys-containing, H6-derived His−Cys hybrid tag that enables the spontaneous and efficient self-assembling of tagged proteins into monodisperse nanoparticles through a highly ordered covalent binding process. Although the generated nanostructures are supported by disulfide bridge formation and exclusively reversed by reducing agents but not by chelating agents, the presence of cysteine residues does not disrupt the metal-binding abilities of histidine residues within the tag. This fact allows one to combine the one-step IMAC-based protein purification and, also, the Zn 2+ -induced formation of higher-order microparticulate materials as nanoparticle-releasing protein-only depots. The dual mode of cross-molecular interactivity shown by the hybrid tag and the structural robustness and stability of the resulting nanoparticles offer wide applicability of the green biofabrication concept proposed here for the further development of clinically usable protein materials.

show abstract

“…Recombinant proteins have been used as drugs for decades [31][32][33][34] and their intrinsic clinical safety and industrial scalability in their production have been largely demonstrated. In addition, the functional and structural versatility of polypeptides allow designing presentations as multimeric, nanoscale materials in which self-assembling is achieved through several alternative approaches [35][36][37][38][39][40][41][42][43]. This set of properties make them excellent candidates for new generation approaches in contemporary vaccinology.…”

Section: Introductionmentioning

confidence: 99%

Recombinant vaccines in 2022: a perspective from the cell factory

et al. 2022

View full text Add to dashboard Cite

The last big outbreaks of Ebola fever in Africa, the thousands of avian influenza outbreaks across Europe, Asia, North America and Africa, the emergence of monkeypox virus in Europe and specially the COVID-19 pandemics have globally stressed the need for efficient, cost-effective vaccines against infectious diseases. Ideally, they should be based on transversal technologies of wide applicability. In this context, and pushed by the above-mentioned epidemiological needs, new and highly sophisticated DNA-or RNA-based vaccination strategies have been recently developed and applied at large-scale. Being very promising and effective, they still need to be assessed regarding the level of conferred long-term protection. Despite these fast-developing approaches, subunit vaccines, based on recombinant proteins obtained by conventional genetic engineering, still show a wide spectrum of interesting potentialities and an important margin for further development. In the 80’s, the first vaccination attempts with recombinant vaccines consisted in single structural proteins from viral pathogens, administered as soluble plain versions. In contrast, more complex formulations of recombinant antigens with particular geometries are progressively generated and explored in an attempt to mimic the multifaceted set of stimuli offered to the immune system by replicating pathogens. The diversity of recombinant antimicrobial vaccines and vaccine prototypes is revised here considering the cell factory types, through relevant examples of prototypes under development as well as already approved products.

show abstract

Building protein networks in synthetic systems from the bottom-up

Cited by 11 publications

References 101 publications

Short Peptide Nanofiber Biomaterials Ameliorate Local Hemostatic Capacity of Surgical Materials and Intraoperative Hemostatic Applications in Clinics

Short Peptide Nanofiber Biomaterials Ameliorate Local Hemostatic Capacity of Surgical Materials and Intraoperative Hemostatic Applications in Clinics

Biofabrication of Self-Assembling Covalent Protein Nanoparticles through Histidine-Templated Cysteine Coupling

Recombinant vaccines in 2022: a perspective from the cell factory

Contact Info

Product

Resources

About